Skip to content
- July 20, 2022
Rheos Medicines Receives FDA “Study May Proceed” Letter to Initiate Phase 1 Clinical Study Under its Investigational New Drug Application for RHX-317 for Treatment of Autoimmune and Inflammatory Diseases
- May 12, 2022
Rheos Medicines CSO Dania Rabah to Deliver Keynote Address at AAPS National Biotechnology Conference
- May 09, 2022
Rheos Medicines Announces Publication of New Data to Support Targeting MALT1 to Treat Autoimmune and Inflammatory Diseases
- April 14, 2022
Rheos Medicines Announces New Scientific Advisory Board Members
- April 14, 2022
Rheos Medicines Appoints Katerina Leftheris, Ph.D., as SVP of Drug Discovery and Nabil Uddin, Pharm.D., as VP of Strategy and Business Development
- December 13, 2021
Rheos Medicines Presents New Data Supporting MALT1 Inhibition as Novel Strategy for Precision Medicine-Based Approach to Treating Chronic Graft-Versus-Host Disease
- December 09, 2021
Rheos Medicines to Participate in the 2021 RBC Capital Markets Healthcare Private Company Conference
- November 04, 2021
Rheos Medicines to Present Data at ASH 2021 for MALT1 Inhibition for Treatment of Graft-Versus-Host Disease
- November 01, 2021
Rheos Medicines Presents Data Demonstrating Potential of MALT1 Inhibition as Novel Approach for the Treatment of Autoimmune and Inflammatory Diseases
- October 27, 2021
Rheos Medicines Forms Research Collaboration with CRYOSTEM to Evaluate MALT1 Targeted Therapeutics for Graft-versus-Host-Disease
- October 13, 2021
Rheos Medicines to Present Data at ACR 2021 for MALT1 Inhibitors in Autoimmune and Inflammatory Disease and Announces RHX-317 as First Development Candidate
- August 09, 2021
Rheos Medicines Appoints Nirupama Subramanian as Chief Operating Officer
- July 12, 2021
Rheos Medicines Appoints Industry Leader, John Davis, Jr., M.D., M.P.H., M.S., to Board of Directors
- May 27, 2021
Rheos Medicines to Present at Jefferies Virtual Healthcare Conference
- December 17, 2020
Rheos Medicines and PatientsLikeMe Announce Strategic Collaboration to Investigate Underlying Metabolic Drivers of Immune-Mediated Disease
- October 21, 2020
Rheos Medicines Appoints Dania Rabah, Ph.D., as Chief Scientific Officer
- September 28, 2020
Rheos Medicines to Participate in Stifel 2020 Immunology and Inflammation Virtual Summit
- February 18, 2020
Rheos Medicines to Present at the Cowen and Company 40th Annual Health Care Conference
- December 19, 2019
Rheos Medicines Announces Worldwide Collaboration with Roche to Discover and Develop Novel Medicines in the Field of Immunometabolism
- December 12, 2019
Rheos Medicines Announces Publication of Perspective in Cell Metabolism Highlighting the Rationale and Potential of Employing Principles of Immunometabolism to Discover and Develop Novel Medicines
- October 21, 2019
Rheos Medicines Appoints Barbara S. Fox as Chief Executive Officer
- March 07, 2019
Rheos Medicines to Present at the Cowen and Company 39th Annual Health Care Conference
- October 10, 2018
Rheos Medicines Expands Leadership Team with Appointments of Gad Soffer as Chief Operating Officer and J. Duncan Higgons to Board of Directors
- March 22, 2018
Third Rock Ventures Launches Rheos Medicines with $60 Million in Series A Funding to Harness Immunometabolism to Develop Precision Medicines for Immune-mediated Diseases